BioStock: SynAct Pharma summarises busy second quarter

05 August 2022 - 10:04

SynAct Pharma's CEO Jeppe Øvlesen and CFO Patrik Renblad visit BioStock's studio to talk about the second quarter report, the uplisting to Nasdaq Stockholm Main Market and the new design for the phase IIa study with AP1189 in idiopathic membranous nephropathy (iMN). In addition, we get to know more about the company's main focus this fall and how long the current cash position will finance the development activities.

Watch the video interview with SynAct Pharma’s CEO and CFO at

This is a pressrelease from BioStock – Connecting Innovation & Capital.

Provided by: Cision
SynAct Pharma AB
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and foremost joint injuries....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More